

Rhythm Pharmaceuticals is a global biopharmaceutical company committed to transforming the lives of patients with rare neuroendocrine diseases.

Rhythm is advancing the clinical development program for setmelanotide, an MC4R agonist, as well as investigational MC4R agonists bivamelagon and RM-718. In addition, we are working to discover and advance new therapeutic options for patients with congenital hyperinsulinism (CHI).

### Rhythm clinical development pipeline:

	Patient Population	Pre-clinical	Phase 1/2	Phase 3	Regulatory Approval
<b>Setmelanotide</b> <i>daily injection</i>	Acquired hypothalamic obesity (4 years of age and older)	Complete	Complete	Complete	US
	Bardet-Biedl syndrome or biallelic POMC, PCSK1 or LEPR deficiency (2 years of age and older)*	Complete	Complete	Complete	US, EU, UK
<b>Setmelanotide</b> <i>daily injection</i> <sup>^</sup>	Congenital hypothalamic obesity	Ongoing	Ongoing	Ongoing	
	Prader-Willi syndrome	Ongoing	Ongoing	Ongoing	
<b>Bivamelagon</b> <i>daily oral formulation</i> <sup>^</sup>	Acquired hypothalamic obesity	Complete	Complete	Phase 3 Preparation	
<b>RM-718</b> <i>weekly injection</i> <sup>^</sup>	Acquired hypothalamic obesity	Complete	Recruiting	Ongoing	
	Prader-Willi syndrome	Ongoing	Recruiting	Ongoing	
<b>Pre-clinical</b>	Congenital hyperinsulinism (CHI)	Ongoing	Ongoing	Ongoing	

Complete Ongoing

\*Approved in Canada (6 years of age and older)

<sup>^</sup>Currently being studied as

For more information regarding clinical study opportunities and our ongoing research, please contact [clinicaltrials@rhythmtx.com](mailto:clinicaltrials@rhythmtx.com) or visit our website at <https://www.rhythmtx.com/>.

Abbreviations: LEPR, leptin receptor; MC4R, melanocortin-4 receptor; PCSK1, proprotein convertase subtilisin/kexin type 1; POMC, proopiomelanocortin.

© 2026 Rhythm Pharmaceuticals, Inc. All rights reserved. Rhythm and its logo are trademarks of Rhythm Pharmaceuticals, Inc. GL-SET-2000006 (12.03/2026)